Summary of the main patient characteristics, response, and toxicity of CAR Tcells
| ID . | Sex . | Age (y) at time of CAR T-cell infusion . | ECOG . | No. and types of prior lines of therapy . | Bridging therapy . | Disease localization at time of CAR T-cell infusion . | Disease status at time of CAR T-cell infusion . | Infused CAR T-cell product . | Maximum CRS/ICANS . | Required treatment of CRS/ICANS . | Cytopenia not resolved by day 28, grade ≥ 3 (type) . | Response at M1 . | Response at M3 . | Subsequent treatment, most recent response . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 69 | 1 | 2 R-MPVA, R-ICE + ASCT (thiotepa-BCNU) | Ibrutinib | Several small nodular left parietal lesions | PR | Tisa-cel | Grade 2 CRS, grade 2 ICANS | Tocilizumab and corticosteroids | No | PR | PR (concurrent ibrutinib) | Progression at M2 ≥ Ibrutinib ≥ CRu finally followed by PD at day 178 Still alive at day 295 |
| 2 | M | 51 | 4 | 3 R-MTX-cytarabine + ASCT (TBC), R-ICE, ibrutinib | MTX-cytarabine- lenalidomide | Necrotic hemorrhagic left temporoparietal lesion of 98 × 74 mm | PD | Tisa-cel | Grade 2 CRS, no ICANS | Tocilizumab and corticosteroids | Yes (thrombocytopenia, neutropenia) | SD | NE | Deceased at day 37 |
| 3 | F | 71 | 3 | 4 R-MTX-cytarabine, R-ICE + ASCT (TBC), temozolomide, ibrutinib | None | Eye + several lesions of the right hemisphere, including a 28 × 23 mm frontal lesion | PD | Axi-cel | Grade 2 CRS, grade 4 ICANS | Corticosteroids | No | PR | CR by brain MRI Eye NE | Persistent CR by brain MRI and clinical improvement at day 350 Eye examination not feasible High level of IL-10 in the anterior chamber (1200 pg/mL) at day 176 |
| 4 | F | 68 | 3 | 4 R-MBVP, R-ICE + ACST (TBC), intrathecal MTX and cytarabine, ibrutinib | R-ibrutinib-lenalidomide | CSF only | PD | Tisa-cel | No CRS, grade 3 ICANS | No | No | CR | CR | Relapse at day 122 Still alive at day 458 after multiple treatments (lenalidomide, ibrutinib, intrathecal rituximab, pomalidomide) |
| 5 | F | 67 | 1 | 3 R-MPVA, R-ICE, ocular RT | R-MTX-procarbazine | Necrotic hemorrhagic bifrontal lesion (right: 28 × 14 mm. Left: 18 × 7 mm) | PR | Tisa-cel | No CRS, no ICANS | NA | No | PD | PD | Still alive at day 261 after multiple treatments (lenalidomide, ibrutinib, pomalidomide, temozolomide) |
| 6 | M | 49 | 1 | 5 R-MTX-cytarabine- temozolomide + ASCT (TB), R-ICE, R-ibrutinib-lenalidomide, ibrutinib-pomalidomide, pomalidomide-nivolumab | MTX-cytarabine | Several small nodular left frontal lesions | PD | Tisa-cel | Grade 2 CRS, grade 1 ICANS | No | No | PD (suspected flare effect) | PD (suspected flare effect) | PD at day 256: near disappearance of all enhanced lesions but increase of an occipital lesion No additional treatment |
| 7 | F | 65 | 1 | 3 R-MPVA, R-ICE, R-ibrutinib-lenalidomide + ASCT (TBC) | MTX | Ventriculitis (right temporal ventricular horn) + 5 mm diameter right frontal lesion | PR | Tisa-cel | Grade 3 CRS, no ICANS | Tocilizumab and corticosteroids | Yes (thrombocytopenia, neutropenia) | PR | CR | Persistent CR at day 209 |
| 8 | F | 48 | 0 | 2 R-MBVP-cytarabine + ASCT (TB), R-lenalidomide | Ibrutinib | 3-mm diameter hypothalamic lesion | PR | Tisa-cel | Grade 1 CRS, no ICANS | Tocilizumab | Yes (pancytopenia) | CR | CR | Persistent CR at day 145 |
| 9 | M | 75 | 0 | 2 R-MPVA, R-MTX | R-lenalidomide | Left temporal lobe (20.5 × 17 × 8.5mm) + perilesional edema | PR | Axi-cel | Grade 1 CRS, grade 1 ICANS | Tocilizumab and corticosteroids | Yes (thrombocytopenia, neutropenia) | CR | CR | Persistent CR at day 210 Deceased from COVID-19 |
| ID . | Sex . | Age (y) at time of CAR T-cell infusion . | ECOG . | No. and types of prior lines of therapy . | Bridging therapy . | Disease localization at time of CAR T-cell infusion . | Disease status at time of CAR T-cell infusion . | Infused CAR T-cell product . | Maximum CRS/ICANS . | Required treatment of CRS/ICANS . | Cytopenia not resolved by day 28, grade ≥ 3 (type) . | Response at M1 . | Response at M3 . | Subsequent treatment, most recent response . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 69 | 1 | 2 R-MPVA, R-ICE + ASCT (thiotepa-BCNU) | Ibrutinib | Several small nodular left parietal lesions | PR | Tisa-cel | Grade 2 CRS, grade 2 ICANS | Tocilizumab and corticosteroids | No | PR | PR (concurrent ibrutinib) | Progression at M2 ≥ Ibrutinib ≥ CRu finally followed by PD at day 178 Still alive at day 295 |
| 2 | M | 51 | 4 | 3 R-MTX-cytarabine + ASCT (TBC), R-ICE, ibrutinib | MTX-cytarabine- lenalidomide | Necrotic hemorrhagic left temporoparietal lesion of 98 × 74 mm | PD | Tisa-cel | Grade 2 CRS, no ICANS | Tocilizumab and corticosteroids | Yes (thrombocytopenia, neutropenia) | SD | NE | Deceased at day 37 |
| 3 | F | 71 | 3 | 4 R-MTX-cytarabine, R-ICE + ASCT (TBC), temozolomide, ibrutinib | None | Eye + several lesions of the right hemisphere, including a 28 × 23 mm frontal lesion | PD | Axi-cel | Grade 2 CRS, grade 4 ICANS | Corticosteroids | No | PR | CR by brain MRI Eye NE | Persistent CR by brain MRI and clinical improvement at day 350 Eye examination not feasible High level of IL-10 in the anterior chamber (1200 pg/mL) at day 176 |
| 4 | F | 68 | 3 | 4 R-MBVP, R-ICE + ACST (TBC), intrathecal MTX and cytarabine, ibrutinib | R-ibrutinib-lenalidomide | CSF only | PD | Tisa-cel | No CRS, grade 3 ICANS | No | No | CR | CR | Relapse at day 122 Still alive at day 458 after multiple treatments (lenalidomide, ibrutinib, intrathecal rituximab, pomalidomide) |
| 5 | F | 67 | 1 | 3 R-MPVA, R-ICE, ocular RT | R-MTX-procarbazine | Necrotic hemorrhagic bifrontal lesion (right: 28 × 14 mm. Left: 18 × 7 mm) | PR | Tisa-cel | No CRS, no ICANS | NA | No | PD | PD | Still alive at day 261 after multiple treatments (lenalidomide, ibrutinib, pomalidomide, temozolomide) |
| 6 | M | 49 | 1 | 5 R-MTX-cytarabine- temozolomide + ASCT (TB), R-ICE, R-ibrutinib-lenalidomide, ibrutinib-pomalidomide, pomalidomide-nivolumab | MTX-cytarabine | Several small nodular left frontal lesions | PD | Tisa-cel | Grade 2 CRS, grade 1 ICANS | No | No | PD (suspected flare effect) | PD (suspected flare effect) | PD at day 256: near disappearance of all enhanced lesions but increase of an occipital lesion No additional treatment |
| 7 | F | 65 | 1 | 3 R-MPVA, R-ICE, R-ibrutinib-lenalidomide + ASCT (TBC) | MTX | Ventriculitis (right temporal ventricular horn) + 5 mm diameter right frontal lesion | PR | Tisa-cel | Grade 3 CRS, no ICANS | Tocilizumab and corticosteroids | Yes (thrombocytopenia, neutropenia) | PR | CR | Persistent CR at day 209 |
| 8 | F | 48 | 0 | 2 R-MBVP-cytarabine + ASCT (TB), R-lenalidomide | Ibrutinib | 3-mm diameter hypothalamic lesion | PR | Tisa-cel | Grade 1 CRS, no ICANS | Tocilizumab | Yes (pancytopenia) | CR | CR | Persistent CR at day 145 |
| 9 | M | 75 | 0 | 2 R-MPVA, R-MTX | R-lenalidomide | Left temporal lobe (20.5 × 17 × 8.5mm) + perilesional edema | PR | Axi-cel | Grade 1 CRS, grade 1 ICANS | Tocilizumab and corticosteroids | Yes (thrombocytopenia, neutropenia) | CR | CR | Persistent CR at day 210 Deceased from COVID-19 |
Response was centrally reviewed by 2 experts and determined according to the IPCG criteria9; grading of CRS and ICANS was determined by the ASTCT scale10; grading of cytopenia was performed with the use of the CTCAE version 5.0.
F, female; M, male; MTX, methotrexate; NE, not evaluable; R-ICE, rituximab, ifosfamide, carboplatine, etoposide; R-MBVP, rituximab, methotrexate, BCNU, etoposide, prednisone; R-MPVA, rituximab, methotrexate, procarbazine, vincristine, aracytine; RT, radiotherapy; TBC, thiotepa, busulfan, cyclophosphamide.